Proinsulin C-peptide (human)
Based on 1 publication(s) in Google Scholar
Proinsulin C-peptide (human) is a peptide consisting of 31 amino acids that links the A and B chains of proinsulin to ensure its correct folding. Proinsulin C-peptide (human) inhibits the high glucose-induced increase in PDGF-β receptor protein expression and the phosphorylation of p42/p44 MAP kinase. Proinsulin C-peptide (human) increases the deformability of erythrocytes derived from type 1 diabetes, inhibits insulin-induced neointimal thickening, and suppresses the proliferation of rat aortic smooth muscle cells cultured under high-glucose conditions.
For research use only. We do not sell to patients.
- Purity: 99.54%
- CAS No.: 33017-11-7
- Formula: C129H211N35O48
- Molecular Weight:3020.26
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Proinsulin C-peptide (human)
More
Biological Activity
|
PDGFRβ |
Human proinsulin C-peptide (0.6-66.6 nmol/l; 4-8 h) restores the impaired erythrocyte deformability of Type I diabetic patient erythrocytes to healthy control levels, an effect dependent on Na+-K+-ATPase activity, but does not alter erythrocyte deformability in healthy control subjects[1].
Proinsulin C-peptide (human) (10 nmol/l; 14 days) fully abrogates insulin-induced neointimal thickening in organ-cultured human saphenous vein segments after 14 days of co-incubation[2].
Human proinsulin C-peptide (1-100 nmol/l; 3 weeks) dose-dependently suppresses high-glucose-induced hyperproliferation of rat aortic smooth muscle cells, A10 cells, with significant inhibitory effects at 10 nmol/l and 100 nmol/l after 3 weeks of treatment[3].
Human proinsulin C-peptide (10-100 nmol/l; 3 weeks) suppresses high-glucose-induced upregulation of PDGF-beta receptor protein expression in rat aortic smooth muscle cells, A10 cells, after 3 weeks of treatment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:rat aortic smooth muscle cells, A10 cells
-
Concentration:1 nmol/l, 10 nmol/l, 100 nmol/l
-
Incubation Time:3 weeks
-
Result:Suppressed high-glucose-induced hyperproliferation in a dose-dependent manner.
Reduced proliferation by 33.9±11.2% relative to high-glucose control at 1 nmol/l.
Reduced proliferation by 48.1±8.7% (p < 0.05) relative to high-glucose control at 10 nmol/l.
Reduced proliferation by 56.9±4.4% (p < 0.01) relative to high-glucose control at 100 nmol/l.
Showed no effect on proliferation under normal 5.5 mmol/l glucose conditions.
-
Cell Line:rat aortic smooth muscle cells, A10 cells
-
Concentration:10 nmol/l, 100 nmol/l
-
Incubation Time:3 weeks
-
Result:Suppressed high-glucose-induced increase in PDGF-beta receptor protein expression.
Produced significant decreases relative to high-glucose control at both 10 nmol/l and 100 nmol/l.
Showed no effect on PDGF-beta receptor expression under normal 5.5 mmol/l glucose conditions.\nReduced high-glucose-induced increase in phosphorylation of p42 and p44 MAP kinases.
Produced significant decreases relative to high-glucose control (p < 0.05) at both 10 nmol/l and 100 nmol/l.
Showed no effect on p42/p44 MAP kinase phosphorylation under normal 5.5 mmol/l glucose conditions.
Chemical Information
-
CAS No. 33017-11-7
-
Appearance Solid
-
Molecular Weight 3020.26
-
Formula C129H211N35O48
-
Color White to off-white
-
Sequence
Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln
-
Sequence Shortening
EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
A wearable device for continuous immunoassay-based monitoring of C-peptide in interstitial fluid. [Abstract]2025 Jul 18;11(29):eadw2182. PMID: 40680118
Solvent & Solubility
DMSO : 100 mg/mL (33.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kunt T, et al. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus. Diabetologia. 1999 Apr;42(4):465-71. [Content Brief]
[2]. Mughal RS, et al. Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia. 2010;53(8):1761-1771. [Content Brief]
[3]. Kobayashi Y, et al. Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia. 2005;48(11):2396-2401. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.3311 mL | 1.6555 mL | 3.3110 mL | 8.2774 mL |
| 5 mM | 0.0662 mL | 0.3311 mL | 0.6622 mL | 1.6555 mL | |
| 10 mM | 0.0331 mL | 0.1655 mL | 0.3311 mL | 0.8277 mL | |
| 15 mM | 0.0221 mL | 0.1104 mL | 0.2207 mL | 0.5518 mL | |
| 20 mM | 0.0166 mL | 0.0828 mL | 0.1655 mL | 0.4139 mL | |
| 25 mM | 0.0132 mL | 0.0662 mL | 0.1324 mL | 0.3311 mL | |
| 30 mM | 0.0110 mL | 0.0552 mL | 0.1104 mL | 0.2759 mL |
Proinsulin C-peptide (human) Related Classifications
Cat. No.: HY-P1856
Powered by Bioz
- Proinsulin C-peptide (human)
- 33017-11-7
- Insulin Receptor
- PDGFR
- MAPKAPK2 (MK2)
- human saphenous vein neointimal thickening
- skin microcirculation
- erythrocyte deformability
- SREBF1
- endothelial nitric oxide synthase
- Na+-K+-ATPase
- human saphenous vein endothelial cell proliferation
- smooth muscle cell migration
- smooth muscle cell proliferation
- type 1 diabetes mellitus
- Inhibitor
- inhibitor
- inhibit